Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Influence of single nucleotide polymorphisms of carboxypeptidase D (CPD) gene on body weight and fat mass reduction by perindopril in obese subjects: A phase II, multicenter, double-blind study.

    Summary
    EudraCT number
    2015-004275-70
    Trial protocol
    PT  
    Global end of trial date
    27 Apr 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    27 Apr 2024
    First version publication date
    27 Apr 2024
    Other versions
    Summary report(s)
    CSR Synopsis
    Trial premature ended

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    GPD-01-01
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Gene PreDiT SA
    Sponsor organisation address
    BIOCANT PARK - Parque Tecnológico de Cantanhede, Núcleo 04, Lote 4-A, Edifício Biocant II, Cantanhede, Portugal, 3060-197
    Public contact
    Gene PreDiT SA, Gene PreDiT SA, 00351 231410893, andre.faustino@genepredit.com.pt
    Scientific contact
    Blueclinical - Investigacao e Desenvolvimento em Saude, Lda, Blueclinical - Investigacao e Desenvolvimento em Saude, Lda, 00351 220995159 , regulatory@blueclinical.pt
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    25 Jul 2017
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Apr 2017
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To evaluate CPD genotyping as a predictive biomarker of body weight and/or fat mass reduction in obese patients treated with perindopril.
    Protection of trial subjects
    This is a Phase II study and was not foreseen additional risks that required additional safety measures.Nevertheless, the safety of the participants was ensured during the whole study.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    02 Mar 2016
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Portugal: 140
    Worldwide total number of subjects
    140
    EEA total number of subjects
    140
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    140
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Subjects were recruited by each clinical trial site based on the eligilibity criteria.

    Pre-assignment
    Screening details
    Screening consisted of discussion of informed consent, collection of demographic data, body height, body weight, body mass index (BMI), waist and hip circumference, body fat measurement, medical history, physical examination, and vital signs. Blood samples were collected for CDP genptyping and for hematology, biochemistry and serum pregnancy tests.

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator
    Blinding implementation details
    By maintaining the CPD genotype blinded until the study database is locked, double blinding was possible without using placebo.

    Arms
    Arm title
    Test
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Perindopril Bluepharma
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Patients were administred perindopril 8 mg, once daily, for 12 weeks, concomitantly with the previously established standardized nonpharmacological therapy.

    Number of subjects in period 1 [1]
    Test
    Started
    134
    Completed
    106
    Not completed
    28
         Adverse event, non-fatal
    9
         Not specified
    18
         Pregnancy
    1
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Actual number of subjects enrolled and analyzed for safety = 140 subjects; number of intention-to-treat (ITT) population = 134; number of per protocol (PP) population = 106 subjects.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial
    Reporting group description
    -

    Reporting group values
    Overall trial Total
    Number of subjects
    134 134
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    134 134
        From 65-84 years
    0 0
        85 years and over
    0 0
    Gender categorical
    Units: Subjects
        Female
    79 79
        Male
    55 55

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Test
    Reporting group description
    -

    Primary: Response rate (proportion of patients who lost at least 3% of body weight from end of the run-in period to the end of the perindopril treatment period)

    Close Top of page
    End point title
    Response rate (proportion of patients who lost at least 3% of body weight from end of the run-in period to the end of the perindopril treatment period) [1]
    End point description
    End point type
    Primary
    End point timeframe
    From end of the run-in period to the end of the perindopril treatment period.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: It is not possible to include a statistical analyses since there is no comparison group in the section "Statistical analyses".
    End point values
    Test
    Number of subjects analysed
    134
    Units: Kg
        least squares mean (confidence interval 95%)
    -0.03 (-0.94 to 0.88)
    No statistical analyses for this end point

    Primary: Response rate (proportion of patients who lost at least 3% of fat mass from end of the run-in period to the end of the perindopril treatment period)

    Close Top of page
    End point title
    Response rate (proportion of patients who lost at least 3% of fat mass from end of the run-in period to the end of the perindopril treatment period) [2]
    End point description
    End point type
    Primary
    End point timeframe
    From end of the run-in period to the end of the perindopril treatment period.
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: It is not possible to include a statistical analyses since there is no comparison group in the section "Statistical analyses".
    End point values
    Test
    Number of subjects analysed
    134
    Units: Kg
        least squares mean (confidence interval 95%)
    0.47 (-0.61 to 1.55)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the start of treatment period to end of treatment period.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    Overall trial
    Reporting group description
    -

    Serious adverse events
    Overall trial
    Total subjects affected by serious adverse events
         subjects affected / exposed
    1 / 140 (0.71%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Pregnancy, puerperium and perinatal conditions
    Pregnancy
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Overall trial
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    87 / 140 (62.14%)
    Vascular disorders
    Haemorrhage
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Hypertension
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Hypotension
         subjects affected / exposed
    4 / 140 (2.86%)
         occurrences all number
    4
    Orthostatic hypotension
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Surgical and medical procedures
    Endodontic procedure
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    General disorders and administration site conditions
    Influenza like illness
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Pyrexia
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Oedema peripheral
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Fatigue
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Reproductive system and breast disorders
    Dysmenorrhoea
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Metrorrhagia
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    2
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    18 / 140 (12.86%)
         occurrences all number
    20
    Dyspnoea
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Laryngeal discomfort
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Rhinorrhoea
         subjects affected / exposed
    3 / 140 (2.14%)
         occurrences all number
    3
    Dry throat
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Oropharyngeal pain
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    3 / 140 (2.14%)
         occurrences all number
    3
    Eating disorder
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Investigations
    Blood glucose abnormal
         subjects affected / exposed
    3 / 140 (2.14%)
         occurrences all number
    3
    Blood glucose increased
         subjects affected / exposed
    4 / 140 (2.86%)
         occurrences all number
    4
    Low density lipoprotein increased
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Blood cholesterol increased
         subjects affected / exposed
    3 / 140 (2.14%)
         occurrences all number
    3
    Weight increased
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Injury, poisoning and procedural complications
    Bite
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Arthropod sting
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Foot fracture
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Limb injury
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Tachycardia
         subjects affected / exposed
    3 / 140 (2.14%)
         occurrences all number
    3
    Nervous system disorders
    Headache
         subjects affected / exposed
    8 / 140 (5.71%)
         occurrences all number
    8
    Dizziness
         subjects affected / exposed
    8 / 140 (5.71%)
         occurrences all number
    8
    Dysgeusia
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Cervical cord compression
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Presyncope
         subjects affected / exposed
    4 / 140 (2.86%)
         occurrences all number
    4
    Balance disorder
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Somnolence
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Paraesthesia
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Radicular pain
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Sciatica
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Tremor
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Blood and lymphatic system disorders
    Eosinophilia
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Microcytosis
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Ear and labyrinth disorders
    Excessive cerumen production
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Vertigo
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Eye disorders
    Macular oedema
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Visual acuity reduced
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Gastrointestinal disorders
    Frequent bowel movements
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Anorectal discomfort
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Dental caries
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Diarrhoea
         subjects affected / exposed
    4 / 140 (2.86%)
         occurrences all number
    4
    Abdominal pain upper
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Dyspepsia
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Haemorrhoids
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Nausea
         subjects affected / exposed
    3 / 140 (2.14%)
         occurrences all number
    3
    Odynophagia
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Toothache
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Vomiting
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Renal and urinary disorders
    Urogenital disorder
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Endocrine disorders
    Hyperprolactinaemia
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    4 / 140 (2.86%)
         occurrences all number
    4
    Arthralgia
         subjects affected / exposed
    4 / 140 (2.86%)
         occurrences all number
    4
    Musculoskeletal pain
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Temporomandibular joint syndrome
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Muscle spasms
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Groin pain
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Pain in extremity
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Exostosis
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Nasopharyngitis
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Tooth abscess
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Influenza
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Gastroenteritis
         subjects affected / exposed
    2 / 140 (1.43%)
         occurrences all number
    2
    Pharyngitis
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Tooth infection
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Urinary tract infection
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Conjunctivitis viral
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Metabolism and nutrition disorders
    Dyslipidaemia
         subjects affected / exposed
    9 / 140 (6.43%)
         occurrences all number
    9
    Decreased appetite
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1
    Hypertriglyceridaemia
         subjects affected / exposed
    3 / 140 (2.14%)
         occurrences all number
    3
    Diabetes mellitus inadequate control
         subjects affected / exposed
    1 / 140 (0.71%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The interim analysis showed no statistically significant effect of perindopril in the primary and secondary efficacy endpoints. Thus, the study was prematurely terminated at Sponsor's decision.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 02:52:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA